HLA-A*0301 & B2M & Survivin Mut (RISTFKNWPK)

The peptide RISTFKNWPK, derived from a survivin mutant, is presented by the HLA-A*03:01/β2m complex and serves as a promising neoantigen target. Its presentation enables cytotoxic T lymphocytes (CTLs) to recognize and attack tumor cells overexpressing this mutated survivin variant, which is often associated with cancer cell survival and therapy resistance, offering a potential avenue for specific immunotherapy.